Citations

Showing 10 of 108104 citations.

The Jarvik 2000 Left Ventricular Assist Device: Results of the United States Bridge to Transplant Trial
Selzman, Craig H. , Feller, Erika , Walker, Jordan C., Sheridan, Brett C. , Daly, Richard C. , Anyanwu, Ani C., Madigan, Dave, Liu, Ping‐Yu , Frazier, O.H., Jorde, Ulrich P. , Griffith, Bartley P. , Silvestry, Scott

Mayo Clinic

ASAIO Journal | April 14, 2022 | Volume: 69 | Issue: 2 | Pages: 174-182

10.1097/mat.0000000000001750 | PMID 35421002 Get It

The Jarvik 2000 bridge to transplant investigational device exemption study was a multicentered, prospective study of 150 UNOS status I patients implanted with the Jarvik 2000 between 2005 and 2012. During the study period, there were numerous modifications of the system that included converting from pin to cone bearings. Results were analyzed for three cohorts: total (n = 150), pin (n = 128), and cone (n = 22). Baseline demographics included age (52 ± 13), gender (79% male), size (BSA 1.98), and etiology (37% idiopathic dilated cardiomyopathy; 43% Ischemic). Seventy percent of patients were either INTERMACS 1 or 2. The primary endpoint—defined as successful transplantation or listing at 180 days (prespecified at 65%; 95% lower CI: 57%)—was successfully achieved for the total cohort (67.3%; 95% CI: 59.5%–74.3%; p = 0.006). In subgroup analysis of the more contemporary, cone-bearing group, the primary endpoint was met in 91% (95% CI: 72%–97.5%; p = 0.001). Compared with pin patients, cone-bearing patients had less hemolysis as well as decreased end-organ dysfunction. Functional and quality of life scores improved after implantation independent type of bearing. In conclusion, despite a particularly sick patient population, the Jarvik 2000 was shown to be effective in supporting the advanced HF patient.
Chemoenzymatic Synthesis of Homogeneous Heparan Sulfate and Chondroitin Sulfate Chimeras
Stancanelli, Eduardo , Wander, Rylee , Li, Jine , Wang, Zhangjie , Arnold, Katelyn , Su, Guowei , Kanack, Adam J. , Pham, Truong Quang , Padmanabhan, Anand , Xu, Yongmei , Kanack, Adam, Liu, Jian , Liu, Wei , Pagadala, Vijayakanth

Mayo Clinic

ACS Chemical Biology | April 14, 2022 | Volume: 17 | Issue: 5 | Pages: 1207-1214

10.1021/acschembio.2c00146 | PMID 35420777 Get It

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
Yetmar, Zachary A. , Khodadadi, Ryan B. , Seville, Maria Teresa , Brumble, Lisa , O’Horo, John C. , Ganesh, Ravindra , Razonable, Raymund R. , Yetmar, Zachary A , Razonable, Raymund R , Khodadadi, Ryan B , Ganesh, Ravindra , O'Horo, John C

Mayo Clinic

Open Forum Infectious Diseases | April 14, 2022 | Volume: 9 | Issue: 7 | Pages: No page available

10.1093/ofid/ofac204 | PMID 35791358 Get It

Abstract Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101
Ritchie, Ellen K. , Klepin, Heidi D. , Storrick, Elizabeth, Major, Brittny , Le‐Rademacher, Jennifer , Wadleigh, Martha , Larson, Richard A. , Roboz, Gail J. , Larson, Richard A , Roboz, Gail J , Le-Rademacher, Jennifer G , Klepin, Heidi D , Walker, Alison

Mayo Clinic

Blood Advances | April 14, 2022 | Volume: 6 | Issue: 12 | Pages: 3812-3820

10.1182/bloodadvances.2021006872 | PMID 35420672 Get It

Abstract Geriatric assessment (GA) predicts survival among older adults with acute myeloid leukemia (AML) treated intensively. We evaluated the predictive utility of GA among older adults treated with low-intensity therapy on a multisite trial. We conducted a companion study (CALGB 361101) to a randomized phase 2 trial (CALGB 11002) of adults ≥60 years and considered “unfit” for intensive therapy, testing the efficacy of adding bortezomib to decitabine therapy. On 361101, GA and quality of life (QOL) assessment was administered prior to treatment and every other subsequent cycle. Relationships between baseline GA and QOL measures with survival were evaluated using Kaplan-Meier estimation and Cox proportional hazards models. One-hundred sixty-five patients enrolled in CALGB 11002, and 96 (52%) of them also enrolled in 361101 (median age, 73.9 years). Among participants, 85.4% completed ≥1 baseline assessment. In multivariate analyses, greater comorbidity (hematopoietic cell transplantation-specific comorbidity index >3), worse cognition (Blessed Orientation-Memory-Concentration score >4), and lower European Organization for Research and Treatment of Cancer global QOL scores at baseline were significantly associated with shorter overall survival (P < .05 each) after adjustment for Karnofsky Performance Status, age, and treatment arm. Dependence in instrumental activities of daily living and cognitive impairment were associated with 6-month mortality (hazard ratio [HR], 3.5; confidence interval [CI], 1.2-10.4; and HR, 3.1; CI, 1.1-8.6, respectively). GA measures evaluating comorbidity, cognition, and self-reported function were associated with survival and represent candidate measures for screening older adults planned to receive lower-intensity AML therapies. This trial was registered at www.clinicaltrials.gov as #NCT01420926 (CALGB 11002).
Clinical Profile of Monomicrobial Corynebacterium Hip and Knee Periprosthetic Joint Infections
Tabaja, Hussam , Tai, Don Bambino Geno , Beam, Elena , Beam, Elena , Tai, Don Bambino Geno , Tabaja, Hussam , Abdel, Matthew P. , Tande, Aaron J.

Mayo Clinic

Open Forum Infectious Diseases | April 14, 2022 | Volume: 9 | Issue: 7 | Pages: No page available

10.1093/ofid/ofac193 | PMID 35873283 Get It

Abstract Background Corynebacterium periprosthetic joint infection (PJI) is a poorly described infectious syndrome. Prior studies included cases of polymicrobial infections. This series describes the clinical characteristics, management, and outcomes of monomicrobial Corynebacterium PJI. Methods We queried the Mayo Clinic Total Joint Registry for cases of monomicrobial Corynebacterium knee and hip PJI in adults (age ≥18 years) between 2010 and 2019. Results A total of 20 (1%) out of 2067 PJI cases met our inclusion criteria. Most were males (55%), and the median age was 64 years. Seventy percent had chronic symptoms (>4 weeks). PJI was delayed to late (>3 months postimplantation) in 90%. Three species were identified: C. striatum (70%), C. jeikeium (20%), and C. amycolatum (10%). All tested isolates were susceptible to vancomycin (100%) and linezolid (100%), and most had a minimum inhibitory concentration ≤0.06 mcg/mL to daptomycin (75%). Other agents were less reliable, with high resistance to oral agents commonly used for suppression. Nineteen patients were treated: 37% debridement and implant retention (DAIR), 47% 2-stage exchange, and 16% resection without reimplantation. Of these, failure occurred in 29%, 11%, and 0%, respectively. Conclusions Corynebacterium PJIs pose a therapeutic challenge due to limited antimicrobial armamentarium and undefined optimal surgical intervention. Vancomycin and linezolid remain the most reliable agents for treatment. DAIR may be attempted for acute PJI, but verification of durable chronic suppression options will be critical for this approach.
Progression of rotator cuff tendon pathology in manual wheelchair users with spinal cord injury: A 1-year longitudinal study
Straaten, Meegan G. Van , Barlow, Jonathan D. , Murthy, Naveen S. , Morrow, Melissa M. , Van Straaten, Meegan G , Barlow, Jonathan D , Murthy, Naveen S , Morrow, Melissa M , Jahanian, Omid

Mayo Clinic

The Journal of Spinal Cord Medicine | April 14, 2022 | Volume: 46 | Issue: 3 | Pages: 466-476

10.1080/10790268.2022.2057720 | PMID 35420535 Get It

Radiology of Intra-Aortic Balloon Pump Catheters
Rhodes, Nicholas G. , Johnson, Tucker F. , Boyum, James H. , Khandelwal, Ashish , Howell, Barrett D., Froemming, Adam T. , Behfar, Atta , Behfar, Atta , Khandelwal, Ashish

Mayo Clinic

Radiology: Cardiothoracic Imaging | April 14, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1148/ryct.210120 | PMID 35506140 Get It

Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Hansford, Jordan R. , Huang, Jie , Endersby, Raelene , Dodgshun, Andrew , Li, Bryan , Hwang, Eugene , Gajjar, Amar , Hoff, Katja von , Wells, Olivia, Wray, Alison, Kotecha, Rishi S. , Raleigh, David R. , Stoller, Schuyler , Mueller, Sabine , Bandopadhayay, Pratiti , Fouladi, Maryam , Onar‐Thomas, Arzu , Gottardo, Nicholas G. , Von Hoff, Katja , Mueller, Sabine , Schild, Steven E. , Fouladi, Maryam , Bouffet, Eric , Hansford, Jordan R , Leary, Sarah , Bouffet, Éric , Huang, Annie

Mayo Clinic

Neuro-Oncology Advances | April 14, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac056 | PMID 35664557 Get It

Abstract Background Pineoblastoma is a rare brain tumor usually diagnosed in children. Given its rarity, no pineoblastoma-specific trials have been conducted. Studies have included pineoblastoma accruing for other embryonal tumors over the past 30 years. These included only occasional children with pineoblastoma, making clinical features difficult to interpret and determinants of outcome difficult to ascertain. Patients and Methods Centrally or independently reviewed series with treatment and survival data from North American and Australian cases were pooled. To investigate associations between variables, Fisher’s exact tests, Wilcoxon-Mann-Whitney tests, and Spearman correlations were used. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used in survival analyses. Results We describe a pooled cohort of 178 pineoblastoma cases from Children’s Oncology Group (n = 82) and institutional series (n = 96) over 30 years. Children <3 years of age have significantly worse survival compared to older children, with 5-year progression-free survival (PFS) and overall survival (OS) estimates of 13.5 ± 5.1% and 16.2 ± 5.3%, respectively, compared with 60.8 ± 5.6% and 67.3 ± 5.0% for ≥3 years old (both P < .0001). Multivariable analysis showed male sex was associated with worse PFS in children <3 years of age (hazard ratio [HR] 3.93, 95% CI 1.80-8.55; P = .0006), suggestive of sex-specific risks needing future validation. For children ≥3 years of age, disseminated disease at diagnosis was significantly associated with an inferior 5-year PFS of 39.2 ± 9.7% (HR 2.88, 95% CI 1.52-5.45; P = .0012) and 5-year OS of 49.8 ± 9.1% (HR 2.87, 95% CI 1.49-5.53; P = .0016). Conclusion Given the rarity of this tumor, prospective, collaborative international studies will be vital to improving the long-term survival of these patients.
Modulation of Interferon-Specific Gene Expression by Albumin-Interferon-α in Interferon-α-Experienced Patients with Chronic Hepatitis C
Balan, Vijayan , Sulkowski, Mark , Lambiase, Louis R., Wiesner, Rusell H, Dickson, Rolland C. , Garcia, Andy, Moore, Paul A. , Yu, Ren, Subramanian, G. Mani , Nelson, David R. , Everson, Gregory T.

Mayo Clinic

Antiviral Therapy | April 14, 2022 | Volume: 11 | Issue: 7 | Pages: 901-908

10.1177/135965350601100710 Get It

Albumin-interferon-α (alb-IFN) is a novel recombinant protein derived from IFN-α2b genetically fused to human albumin. The resulting single polypeptide combines in one molecule the antiviral properties of IFN-α with the long serum half-life of albumin. IFN-mediated biological responses stem from the engagement of IFN-α with its target receptor and subsequent modulation of IFN-specific gene (ISG) expression. To evaluate the pharmacodynamics of alb-IFN during the Phase I/II study conducted in patients with chronic hepatitis C (CHC) who had previously failed IFN-α-containing regimens, ISG induction was evaluated in peripheral blood and compared with antiviral response. Whole blood was obtained at day 0, day 7 and day 28 from 21 patients enrolled in the higher dose (500–900 μg) alb-IFN cohort, who received two injections on day 0 and day 14. Taqman real-time PCR was used to assess candidate ISG expression. There was sustained induction on day 7 and day 28 of the ISG's OAS1, IRF-7, IFI44 and IFI27. Although all patients showed a molecular response to alb-IFN, individual variability in pretreatment gene expression levels and fold of modulation during treatment was observed. At day 28, induction of OAS1, IFI44 and IRF7 showed pairwise correlation in individual patients ( P<0.05). Moreover, the induction of expression at day 28, and pretreatment levels of OAS1 and IFI44 correlated with hepatitis C virus RNA reduction at day 28 ( P<0.05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-α.
A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy
Balan, Vijayan , Sulkowski, Mark , Lambiase, Louis R., Wiesner, Rusell H, Dickson, Rolland C. , Post, Anthony B., Redfield, Robert R. , Davis, Gary L. , Neumann, Avidan U. , Osborn, Blaire L., Freimuth, William W., Subramanian, G. Mani , Nelson, David R. , Everson, Gregory T.

Mayo Clinic

Antiviral Therapy | April 14, 2022 | Volume: 11 | Issue: 1 | Pages: 35-45

10.1177/135965350601100111 Get It

Albumin-interferon-α (IFN-α) is a novel 85.7–kDa recombinant protein consisting of IFN-α that is genetically fused to human serum albumin. In this Phase I/II, multicentre, open-label study, we evaluated the safety and tolerability, pharmacokinetics and pharmacodynamics of albumin-IFN-α in IFN-α-experienced patients with chronic hepatitis C. Albumin-IFN-α was administered in 22 escalating doses (7–900 μg) in a single injection or in two injections 14 days apart. In the 119 patients studied, there were no discontinuations because of adverse events, and albumin-IFN-α had a favourable safety profile at doses up to 900 μg. The most common adverse events were headache (56%), fatigue (52%), injection site erythema (38%), arthralgias (32%) and pyrexia (27%). Reduced clearance resulted in a mean elimination half-life of 159h, which supports dosing at 2- to 4-week intervals. Induction of the IFN-specific gene OAS1 was maintained for ≥28 days following a single injection of albumin-IFN-α at doses of ≥40 μg. Dose-dependent antiviral activity was observed in this IFN-α-experienced study population. Antiviral activity of ≥1.0–log reductions in HCV RNA was observed in 47% (37/78) of patients in the 120- to 900-μg cohorts and in 59% (16/27) in the 400- to 900-μg double-injection cohorts. These results support further clinical studies of albumin-IFN-α for the treatment of patients with chronic hepatitis C.